Treatment of submasive pulmonary embolism with low-molecular-weight herapin;Tratamiento de la embolia pulmonar submasiva con heparina de bajo peso molecular

Medicina Clinica

Volumn 115, Issue 9, 2000, Pages 343-346

  Monreal Bosch, M ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Deep vein thrombosis; Low molecular weight heparin; Pulmonary embolism; Survival; Treatment

Indexed keywords

BEMIPARIN; BOXOL; DALTEPARIN; DECIPAR; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN; UNCLASSIFIED DRUG;

DEEP VEIN THROMBOSIS; LUNG EMBOLISM; REVIEW; SURVIVAL RATE;

EID: 0034706154     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(00)71552-1     Document Type: Review

References (50)

1. Autopsy-verified pulmonary embolism in a surgical department: Analysis of the period from 1951 to 1988
2. Incidence of venous thromboembolism verified by necropsy over 30 years
3. The prevalence of risk factors for venous thromboembolism among hospital patients
4. A prospective study of the incidence of deep-vein thrombosis within a defined urban population
5. Acute pulmonary embolism: Clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER)
6. Recurrent pulmonary embolism. A prospective study
7. Recurrent pulmonary embolism in patients treated because of acute venous thromboembolism: A prospectiva study
8. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism
9. Low molecular weight heparin is an effective safe treatment for venous thromboembolism
10. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deepvein thrombosis: A Polish multicentre trial
11. Continuous intravenous heparin compared with intermittent sucutaneous heparin in the initial treatment of proximal-vein thrombosis
12. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis
13. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis
14. Subcutaneous low-molecular-weight heparina compared with continuous heparin in the treatment of proximal-vein thrombosis
15. Sucutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis
16. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis
17. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis
18. Serial impedance plethysmography for suspected deep venous thrombosis in outpatients
19. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombisis
20. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deepvein thrombosis
21. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home
22. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis
23. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis
24. Diagnostic efficacy of impedance plethysmography for clinically suspected deep-vein thrombosis
25. Comparison of oncedaily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis
26. Optimal duration of oral anticoagulant therapy: A randomized trial comparing four weeks three months of warfarin in patients with proximal deep veint thrombosis
27. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis
28. The duration of oral anticoagulation after deep vein thrombosis
29. Two daily sucutaneous injections of Fragmin as compared with intravenous standard heparin in the treatment of deep veint thrombosis (DVT)
30. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism
31. A noninvasive strategy for the treatment of patients with suspected pulmonary embolism
32. Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan
33. The clinical course of pulmonary embolism
34. Streptokinase therapy for deep vein thrombosis: A comprehensive review of the english literature
35. A decision analysis of streptokinase plus heparin as compared with heparin alone for deep-vein thrombosis
36. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of sucbutaneous heparin
37. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: A meta-analysis
38. Low molecular weight heparin in prevention of perioperative thrombosis
39. Adverse effects of three different forms of heparin therapy: Thrombocytopenia, increased transaminases, and hyperkalaemia
40. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin
41. Comparison of efficacy and safety of low molecular weight heparins and unfractinated heparin in initial treatment of deep venous thrombosis: A meta-analysis
42. Treatment of deep-vein thrombosis with low molecular weight heparin. A metaanalysis
43. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
44. Subcutaneous low-molecular-weight heparin Fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: An open randomized pilot study
45. A clinical trial of vena cava filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis
46. Bioavailability and pharmacokinetics of a new low-molecular-weight heparin (RO-11)- a three way croos-over study in healthy volunteers
47. Kinetic behaviour of the TFPI and anti-Xa effects, after the injection of a LMWH (RO-11) in healthy subjects
48. Prophylaxis of thromboembolic disease with RO-11 (ROVI), during abdominal surgery. EMRO1 (Grupo Estudio Multicentrico RO-11)
49. Pharmacokinetics and tolerability of a new low molecular mass heparin (RO-11) in healthy volunteers. A dose-finding study within the therapeutical range
50. Tissue factor pathway inhibitor and anti-FXa kinetic profiles of a new low-molecular-mass heparin, Bemiparin, at therapeutic subcutaneous doses